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Abstract Apnea of prematurity (AOP) is a common
problem affecting premature infants, likely secondary to a
“physiologic” immaturity of respiratory control that may be
exacerbated by neonatal disease. These include altered
ventilatory responses to hypoxia, hypercapnia, and altered
sleep states, while the roles of gastroesophageal reflux and
anemia remain controversial. Standard clinical management
of the obstructive subtype of AOP includes prone position-
ing and continuous positive or nasal intermittent positive
pressure ventilation to prevent pharyngeal collapse and
alveolar atelectasis, while methylxanthine therapy is a
mainstay of treatment of central apnea by stimulating the
central nervous system and respiratory muscle function.
Other therapies, including kangaroo care, red blood cell
transfusions, and CO2 inhalation, require further study. The
physiology and pathophysiology behind AOP are dis-
cussed, including the laryngeal chemoreflex and sensitivity
to inhibitory neurotransmitters, as are the mechanisms by
which different therapies may work and the potential long-
term neurodevelopmental consequences of AOP and its
treatment.
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Introduction
During the first few days of life, premature infants
encounter problems with temperature regulation, acquisi-
tion of oral feeding skills, and the normal control of
respiration [85]. Resolution of apnea and establishment of a
normal respiratory pattern is a major developmental
milestone for many premature infants. The most widely
used definition of apnea of prematurity (AOP) specifies a
pause of breathing for more than 15–20 s, or accompanied
by oxygen desaturation (SpO2≤80% for ≥4s )a n d
bradycardia (heart rate<2/3 of baseline for ≥4 s), in infants
born less than 37 weeks of gestation [55].
While AOP is a developmental disorder, the reasons
behind the propensity for apnea in immature infants are not
entirely clear. Although the pathogenesis of AOP is poorly
understood, the immature pulmonary reflexes and breathing
responses to hypoxia and hypercapnia likely contribute to
the occurrence or severity of AOP [24, 70]. It may also be
exacerbated by a number of coexisting factors or disease
states [6, 52].
Severe apnea that lasts longer than 20 s is usually
associated with bradycardia or desaturation, which may
lead to disturbances of cerebral hemodynamics and possi-
bly affect neurodevelopmental outcome. However, it is
difficult to prove a link between apnea and poor neuro-
developmental outcomes due to a number of comorbidities
and confounding factors affecting neurological develop-
ment in premature infants. Therefore, evaluating the
consequences of AOP on long-term neurodevelopment
remains a challenge.
AOP treatment options are fairly limited and include
prone positioning, methylxanthine therapy, and nasal
intermittent positive pressure ventilation (NIPPV) or con-
tinuous positive airway pressure (CPAP) [34, 54, 63, 71].
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inhalation, and red blood cell transfusions are not widely
used and require further examination [3, 8, 13]. Since the
pathogenesis and long-term neurodevelopmental effects of
AOP are poorly understood, and the optimal treatment for
AOP is not clear, this review discusses recent findings
regarding pathogenesis, mechanisms underlying treatment,
and consequences of AOP in premature infants.
Incidence
The incidence of AOP is inversely correlated with
gestational age and birth weight. Seven percent of neonates
born at 34 to 35 weeks gestation, 15% at 32 to 33 weeks,
54% at 30 to 31 weeks [50], and nearly all infants born at
<29 weeks gestation or <1,000 g exhibit AOP [73]. It is
generally broken down into three subtypes: central, ob-
structive, or mixed [85]. Central apnea accounts for
approximately 10% to 25% of all cases of apnea, with
obstructive apnea accounting for 10% to 25% and mixed
for 50% to 75%. In each individual infant, one of these
subtypes tends to predominate [85].
The incidence of bradycardia is fairly similar across
these different groups; however, bradycardia does appear to
occur more frequently with longer duration of apnea.
Bradycardia occurs in 10% of apneic events with duration
of 10–14 s, 34% of apnea lasting 15–20 s, and 75% of
apnea that lasts >20 s. Bradycardia usually occurs follow-
ing oxygen desaturation that is associated with apnea, with
a recent study demonstrating an earlier onset of oxygen
desaturation than bradycardia (median interval 4.2 s) [68].
However, recovery from bradycardia often precedes the
recovery in oxygen saturation after apnea [68]. Bradycardia
may also follow apnea without desaturation, possibly
mediated by vagal nerve stimulation and not necessarily
by hypoxemia.
Pathogenesis
AOP is a developmental disorder that self-resolves. In most
cases, AOP likely reflects a “physiological” rather than a
“pathological” immature state of respiratory control.
Fetal to neonatal transition
The fetus moves from an oxygen-poor environment, with
PaO2 of 23–27 mmHg, to an oxygen-rich environment after
birth that provides a fourfold increase in PaO2 [51]. The
postnatal rise in PaO2 effectively silences peripheral chemo-
receptors, resulting in delayed onset of spontaneous breath-
ing, especially when neonates are exposed to 100% oxygen
during postnatal resuscitation [94]. Therefore, neonates need
to quickly adjust their ventilation to adapt to the postnatal
environment. The immature respiratory pattern and chemo-
receptor function in premature infants may delay this
postnatal adjustment, given fewer synaptic connections and
poor myelination of the immature brainstem [25].
Ventilatory response to hypoxia
The ventilatory response to hypoxia after birth in premature
infants elicits an initial transient increase in respiratory rate
and tidal volume that lasts for 1–2 min, followed by a late,
sustained decline in spontaneous breathing that may last for
several weeks [31, 59]. This late decline in spontaneous
breathing is termed hypoxic ventilatory depression, which
may be associated with the delayed postnatal respiratory
adjustment that occurs in premature infants.
Peripheral chemoreceptor stimulation may also lead to
apnea secondary to hypocapnia seen after hyperventilation
[17]. The CO2 level can decrease to a level near the apneic
threshold (1–1.3 mmHg below baseline CO2 level) [42].
The relative proximity of the apneic threshold of CO2,
together with peripheral chemoreceptor activation in re-
sponse to hyperventilation, may lead to apnea.
Ventilatory response to hypercapnia
In response to hypercapnia, premature infants increase
ventilation by prolonging the period of expiration, but not
increasing breath frequency or overall tidal volume, leading
to less minute ventilation than that seen in term infants.
This poor hypercapnic ventilatory response is more
pronounced in premature infants with apnea than without
apnea [24]. Contradictory movements of respiratory
muscles in response to hypercapnia may also play a role
in AOP. In a study of piglets exposed to hypercapnia,
researchers found that resultant diaphragm activation prior
to upper airway muscles activity results in obstructed
inspiratory efforts and prolonged apneic events [18].
Ventilatory responses to laryngeal chemoreflex
Activation of the laryngeal mucosa in premature infants can
lead to apnea, bradycardia, and hypotension [70]. While
this response is assumed to be a protective reflex, an
exaggerated response may cause AOP. This reflex-induced
apnea is termed the laryngeal chemoreflex and is mediated
through superior laryngeal nerve afferents [41, 83, 87].
Neurotransmitters and apnea
Enhanced sensitivity to inhibitory neurotransmitters, such
as gamma-aminobutyric acid (GABA), adenosine, seroto-
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infant’s respiratory control system [50]. GABA is the major
inhibitory neurotransmitter in the CNS. In piglets,
GABAergic neurons were activated during hypercapnia
[99]. Blocking of GABAA receptors prevented ventilatory
depression and increased respiratory rate in response to
hypercapnia [78].
Adenosine is a product of adenosine triphosphate and is
formed as a consequence of metabolic and neural activity in
the brain, especially during hypoxia. Recent reports have
found an interaction between adenosine and GABA in the
regulation of breathing [1, 98]. This association is further
strengthened by the observations that adenosine receptors
are expressed in GABA-containing neurons. The binding of
adenosine to its receptor may be involved with the release
of GABA and thus inhibit respiration leading to apnea [98].
Genetic variability and apnea
Recently, researchers found that the heritability of AOP was
87% among same-gender twins [12]. These findings raise
the possibility that AOP has an important genetic basis.
Tamim et al. [86] first reported a higher proportion of first-
degree mating for infants with AOP compared with those
without AOP. Genomic studies may provide further
information on the pathogenesis that underlies AOP.
Effects of sleep state and movements on apnea
Breathing and behavioral states are closely interrelated [44].
Premature infants spend a large proportion of their time in
rapid eye movement (REM) sleep, with a relatively smaller
amount in wakefulness. During REM sleep, these infants
have more paradoxical breathing with a less stable baseline
of oxygen saturation [69]. Therefore, apnea occurs more
frequently in REM sleep than in quiet sleep [44, 74].
Arousal from REM sleep appears to be a precursor to apnea
associated with oxygen desaturation in premature infants
since motor activities after arousal are typically associated
with laryngeal closure [44]. Therefore, movements fre-
quently precede or occur simultaneously with apnea, and
arousal from sleep may cause the apnea rather than
terminate it.
Factors involved in apnea
While immature respiratory control is the primary cause of
apnea in the premature infant, many coexisting factors can
potentiate or worsen apnea. Apnea is a common presenting
sign of both local and systemic infection [39, 84]. Apnea
can be triggered by a number of central nervous system
diseases, including intracranial hemorrhage, hypoxic-
ischemic encephalopathy, and seizures. Thermoregulation
may also play a role in apnea. Exposure to cooler temper-
atures decreased the duration and frequency of AOP, while
elevated body temperature increased the incidence of AOP,
suggesting that apnea is related to metabolic state and
environmental temperature [91].
Other factors that have been associated with apnea in
premature infants include glucose or electrolyte imbalance
[85], as well as the presence of a patent ductus arteriosus
with a large shunt [58]. A number of medications, including
narcotic analgesics and magnesium sulfate, can lead to apnea
in infants [85]. Anemia is also associated with apnea because
of lowered oxygen-carrying capacity of red blood cells that
leads to hypoxia, resulting in respiratory depression [11].
Gastroesophageal reflux and AOP are both occurring
commonly in premature infants. However, the relationship
between themremains controversial.Slocum etal. [89]s e tu p
a reflux model with rapid infusions of graded volumes of air
into the esophagus of newborns to study this association.
They did not find an association with apnea. Esophageal pH
monitoring is the conventional method to test for the
presence of acid reflux from the stomach [27]. Since infants
receive frequent milk-based feedings, which continually
buffer stomach acid, measured pH may be neutral or even
alkaline in some cases [20]. Therefore, esophageal pH may
significantly underestimate the frequency of reflux episodes
in premature infants and may not identify AOP events
resulting from nonacid reflux [20]. Multichannel intra-
luminal impedance technology has been used recently to
monitor electrical impedance in the esophagus, which may
provide a more comprehensive measure of reflux. In
conjunction with pH measurement, multichannel intralumi-
nal impedance can increase the sensitivity of reflux detection
and the identification of both acid and nonacid reflux [21].
Even with these improved detection methods, researchers
have not found an association between gastroesophageal
reflux and apnea [56, 65]. Therefore, the majority of apneic
episodes do not appear to be related to gastroesophageal
reflux, though in a specific subset of events, a causal
relationship may exist [80]. As a result, there is no evidence
to support the use of anti-reflux medications for the
treatment of AOP [89]. On the other hand, apnea may
periodically lead to increased reflux. Recently, researchers
found that the lower esophageal sphincter pressure was
decreased during apneic episodes [61].
Other factors—including neck flexion, nasal obstruction,
and delayed gastric emptying—have also been linked to
apnea. Neck flexion interferes with neuromuscular regula-
tion of pharyngeal patency and can produce intermittent
airway obstruction [95]. Nasal edema or the presence of a
nasogastric feeding tube also increases nasal airway
resistance. Delayed gastric emptying can also increase
Eur J Pediatr (2011) 170:1097–1105 1099apneic events since abdominal distension reduces lung
volume and increase vagal afferent feedback [88].
Interventions for premature infants with apnea
Interventions for AOP include efforts to reduce work of
breathing and/or increase respiratory drive. The latest in
AOP treatment will be discussed below.
Effective interventions
Prone position
Prone positioning can improve thoracoabdominal synchro-
ny and stabilize the chest wall without affecting breathing
pattern or SpO2 [60]. Several studies have demonstrated
that prone position reduces AOP [10, 69]. Extension of the
neck 15° from the prone position is referred to as the head
elevated tilt position, which has been found to decrease
episodes of oxygen desaturation by 48.5% [77]. A more
comfortable three-stair-position that maintains the head and
abdomen in a horizontal position was reported to improve
apnea, bradycardia, and desaturation [7]. However, head
elevated tilt position has not been shown to work in
combination with pharmacologic therapy. Recently, two
randomized controlled trials investigated the effect of three
different postural interventions on the incidence of brady-
cardia and desaturation. The researchers found that the
effect of head elevated tilt position and three-stair-position
interventions following aminophylline treatment was sim-
ilar to standard prone positioning and only decreased the
rate of desaturation by 12% [7, 71]. Thus, in infants
receiving other effective treatment, neither head elevated tilt
position nor three-stair-position resulted in a further
improvement in AOP. Since head elevated tilt position
and three-stair-position are easy to provide, it should be
considered as a first-line intervention in infants with AOP.
Continuous positive airway pressure and nasal intermittent
positive pressure ventilation
CPAP at 4–6 cmH2O has proven a safe and effective
therapy for AOP over the past 35 years. CPAP delivers a
continuous distending pressure via the infant’s pharynx to
the airways to prevent both pharyngeal collapse and
alveolar atelectasis. Therefore, CPAP can enhance func-
tional residual capacity and reduce the work of breathing,
improving oxygenation and decreasing bradycardia [26,
63]. CPAP works effectively to reduce the incidence of
obstruction, but it has no clear efficacy in central AOP [53].
An extension of CPAP is the administration of NIPPV.
Systematic meta-analysis has shown it to be effective in
preventing extubation failure and for the treatment of AOP
[45]. A randomized crossover trial [63] found that variable-
flow nasal continuous positive airway pressure (NCPAP) is
more effective in treating AOP than a conventional
ventilator using NIPPV mode. In a word, reduced work of
breathing may be the key to improving AOP, which can be
achieved via either synchronized NIPPV [54] or variable-
flow NCPAP devices [63].
Methylxanthine therapy
Methylxanthine compounds such as caffeine, theophylline,
and aminophylline have been administered to premature
infants as respiratory stimulants to decrease AOP [50].
These drugs are powerful central nervous system stimulants
and likely reduce apnea by multiple physiological and
pharmacological mechanisms. They are non-selective
antagonists of adenosine receptors that increase minute
ventilation, CO2 sensitivity, and neural respiratory drive
while decreasing the hypoxic depression of breathing.
Methylxanthines also improve diaphragmatic contraction
and respiratory muscle function [4, 34, 57].
Systematic reviews of caffeine therapy in AOP have
shown that both caffeine and theophylline are effective in
reducing apnea within 2 to 7 days of starting treatment.
Caffeine is safer and has a wider therapeutic range than
theophylline [12], and the plasma half-life of caffeine is
100 h compared to 30 h for theophylline [57]. A recent
multicenter clinical trial has resolved the longstanding
uncertainty about the long-term safety and efficacy of
methylxanthine therapy as treatment for AOP. It revealed
that caffeine reduced the rate of bronchopulmonary dyspla-
sia and neurodevelopmental disabilities [75, 76]. Although
the potential mechanisms of neuroprotective effect are not
completely known, the decrease of ventilator-induced lung
injury due to the use of caffeine may partly explain the
neuroprotective outcome.
At what doseshouldcaffeine begiven?Because caffeine is
usually available as caffeine citrate, the active component
comprisesonly50%ofthetotaldose.Inastudyofcaffeinefor
AOP, a loading dose of 10 mg⁄kg caffeine (i.v. or orally) and a
maintenance dose of 2.5 mg⁄kg once daily worked efficiently
[76] .Ar a n d o m i z e dc o n t r o l l e dt r i a l[ 82] compared three
loading doses of 30, 15, or 3 mg/kg of caffeine followed by
half of the loading doses every 24 h. The two higher dose
groups had less apnea than the lowest dose group. In another
randomized controlled trial, Steer et al. [81] compared a very
high loading dose of 40 mg/kg caffeine (followed by 20
mg/kg every 24 h) with a standard loading dose of 10 mg/kg
(followed by 5 mg/kg every 24 h). The high-dose group
showed significant reductions in extubation failure, duration
of ventilation, and apnea after extubation compared with the
low-dose group. Thus, a higher dose of caffeine appears to
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dose of caffeine was reported to have adverse effects.
Hoecker et al. [35] found that a high loading dose of
25 mg/kg of caffeine reduced blood flow velocity in the
cerebral arteries of premature infants by about 20%, whereas
a loading dose of 10 mg/kg caffeine resulted in reduction of
cerebral blood flow velocity that recovered 4 h post-dose
[92]. Therefore, caffeine at a loading dose of 10 mg⁄kg
followed by 5 mg⁄kg⁄day maintenance may be an adequate
starting point. Only when refractory AOP persists should a
switch to a higher dose be considered [81]. For theophylline
use, the recommended loading dose is 5–6m g / k g ,f o l l o w e d
by maintenance doses of 2–6 mg/kg/day divided into two or
three daily doses [92].
Methylxanthines do carry some risks of adverse events.
Toxic levels may produce tachycardia, cardiac dysrhyth-
mias, and feeding intolerance or, at very high doses, may
precipitate seizures. Mild diuresis and delayed gastric
emptying can also be seen in very low birth weight infants.
Methylxanthines also increase energy expenditure, possibly
leading to diminished growth in premature infants, suggest-
ing an extra caloric requirement is necessary in infants
treated with theophylline [2, 19, 79].
Other interventions with unclear efficacy
Kangaroo mother care
Maternal kangaroo care, also known as skin-to-skin care for
premature infants, has achieved widespread acceptance for
stable infants because of the calming effects on the baby’s
clinical status and vital signs [30]. However, the effect of
this approach for the treatment of AOP remains controver-
sial. A randomized controlled trial showed that infants
receiving kangaroo care had fewer apneic and bradycardic
events than those who did not receive kangaroo care [46].
In a different study, researchers found that apneic and
bradycardic events were increased during kangaroo care
[16]. Recently, Heimann et al. [33] found that the effect of
kangaroo care on improvement of apnea was the same as
that seen with prone positioning. The use of kangaroo care
for treatment of AOP still requires further study.
Sensory stimulations
Several studies suggest that sensory stimulants, including
tactile and olfactory stimulation, are useful in the treatment
or prevention of AOP. Tactile stimulation is the most
common intervention in response to AOP. This simple
intervention most likely works by generating excitatory,
nonspecific neuronal activity in the brainstem center to
stimulate respiratory activity [32]. An older randomized
controlled trial showed that tactile stimulation reduced the
frequency of apnea by 35% [40]. However, cutaneous
stimulation often arouses the infant and markedly affects
breathing pattern in premature infants. Bloch-Salisbury et
al. [13] have demonstrated that subthreshold stimulation for
causing arousal from sleep to wakefulness could decrease
apnea by approximately 65%. However, systematic review
has shown that kinesthetic stimulation is not effective at
preventing AOP [62].
Olfactory stimulation has also been used for the treatment
of AOP. Pleasant odors elicited increased respiratory drive,
whereas unpleasant odors caused decreased respiratory effort,
duringactivesleepwhenapneaismorecommon[5]. Vanillin,
a stimulus known to affect the olfactory nerve, was used to
treat refractory apnea and bradycardia unresponsive to both
caffeine and doxapram [49]. They found that patients
exposed to 15 drops of vanillin had significantly fewer
apneic episodes [49]. Therefore, researchers concluded that
the presence of a pleasant odor helped the infants to better
regulate their respiratory patterns. Since this experiment was
performed for only 24 h, it is not known how long this
beneficial effect persists.
CO2 inhalation
CO2 is the physiologic stimulus for breathing in mammals.
Apnea occurs when the CO2 baseline decreases below the
apnea threshold. A rise in CO2 of 1 to 2 mmHg above the
apnea threshold will reduce or abolish apnea [38, 42].
Recently, a randomized controlled trial of theophylline
versus CO2 inhalation for treating AOP showed that
inhalation of a low CO2 concentration (0.8%) in premature
infants is as effective as theophylline in decreasing apnea.
This exposure to 0.8% CO2 also had no effect on cerebral
blood flow velocity [3]. The authors concluded that CO2
may be a better treatment for AOP than methylxanthines.
However, it is likely that infants will quickly accommodate
to an inspiratory CO2 concentration, and the effectiveness
of long-term exposure is not known.
Orogastric feeding tube placement
An increase in upper airway resistance may also play a
significant role in AOP. Nasogastric tubes have been
documented to increase nasal airway resistance by 50%
[15]. Therefore, orogastric feeding tubes are sometimes
preferred in premature infants with apneic events. However,
a recent randomized controlled trial showed that the
placement of the feeding tube had no significant effect on
bradycardia and desaturation [15]. There does not appear to
be a benefit of using an oral instead of a nasogastric tube
for feeding infants with AOP. Interestingly, transpyloric
feedings, especially when limited to human milk, have
recently been shown to be safe and reduce episodes of
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gastroesophageal reflux in a retrospective single-center
cohort study [47].
Thermoneutral range
A mild increase in body temperature in infants enhances the
instability of the breathing pattern [72]. In a recent study,
less apnea was found at an incubator temperature of 30.4°C
than at 32.5°C [91]. Of course, a number of factors play a
role in incubator and baby temperature, but overheating
may be a factor in AOP. However, a specific environmental
temperature to reduce the incidence or severity of AOP is
not known, and more research is required.
Red blood cell transfusions
Anemia can lead to AOP, and a proposed mechanism to treat
AOP is transfusion of red blood cells to increase oxygen
carrying capacity. However, data on the effect of blood
transfusion on AOP is not clear. Studies focusing on
bradycardia caused by apnea showed no effect of transfusion
in either mildly or severely anemic infants [96]. Recently, a
randomized trial [8] comparing a liberal with restrictive
transfusion pattern in premature infants found that infants
had more frequent apnea in the restrictive transfusion group.
Furthermore, a retrospective study on the risks and benefits
of transfusions in extremely low birth weight infants found
that transfusions were not associated with apnea frequency
but were associated with increased risk of bronchopulmonary
dysplasia and necrotizing enterocolitis [93]. Based on these
conflicting data, we think that the evidence is insufficient to
recommend transfusion to treat AOP in anemic infants.
Doxapram
Doxapram is a potent respiratory stimulant used for the
management of apnea refractory to methylxanthine therapy
[14]. The use of doxapram is controversial because of its
reported adverse effects [14, 97]. The short-term side
effects of Doxapram include irritability, elevated blood
pressure, and gastric retention, which are usually seen
clinically with doses above 1.5 mg/kg/h [9]. The long-term
side effects of doxapram remain unknown. Dani et al. [23]
evaluated the effects of doxapram on cerebral hemodynam-
ics in premature infants, using cerebral Doppler ultraso-
nography and near-infrared spectroscopy. They found
doxapram induced an increase in cerebral oxygen con-
sumption and a decrease in oxygen delivery. This is
probably mediated by a decrease of cerebral blood flow.
Therefore, doxapram is not routinely recommended for
AOP since its side effects and long-term benefits versus
potential harm are concerning.
Consequences of AOP
Short-term consequences
In premature infants, desaturation and bradycardic episodes
often occur along with apnea. Bradycardia usually begins
after the onset of hypoxemia and can initially be accompanied
by a rise in stroke volume [68]. However, prolonged apnea
and bradycardia can decrease the systemic blood pressure
and lead to cerebral hypoperfusion, which may contribute to
hypoxic-ischemic injury of the immature brain [66].
Long-term consequences
The long-term consequences of apnea are controversial
[64]. It is difficult to prove a link between apnea and poor
neurodevelopmental outcomes due to the possible coexis-
tence of neurological injury in premature infants.
In early studies, no differences in neurodevelopmental
outcomes were found between AOP and control infants.
Delayed mental and motor development was seen in both
premature infant groups [43]. However, Janvier et al. [37]
found that an increased number of AOP days were
associated with neurodevelopmental impairment such as
cerebral palsy and blindness at 3 years of age. Recently,
researchers found that a higher frequency and severity of
AOP were associated with a higher incidence of unfavor-
able outcomes or death [67]. One explanation for these
findings is that multiple recurrent hypoxic and bradycardia
following AOP may cause long-term cerebral dysfunction.
However, these two studies did not establish whether apnea
was a cause or a result of underlying cerebral dysfunction.
Whether persistent AOP may lead to sudden infant death
syndrome was only recently clarified. The risk of sudden
infant death syndrome in premature infants is three times
higher than that of full-term infants [36]. However, the risk
factors for sudden infant death syndrome in premature
infants are strongly associated with maternal age, tobacco
use, meteorological factors, and genetics but not AOP [22,
28, 48, 90].
Generally speaking, the lower the gestational age, the
longer the period that AOP persists. AOP disappears in
most infants by 36 to 40 weeks postconceptional age.
However, extremely premature infants (24–28 gestational
weeks) are at risk for experiencing apnea beyond 38 to
40 weeks postconceptional age [29].
Summary
Apnea is a very common symptom in premature infants. In
the majority of infants, apnea is a time-limited problem,
disappearing by term postconceptional age. The long-term
1102 Eur J Pediatr (2011) 170:1097–1105consequences of severe, recurrent apnea-associated brady-
cardia and desaturation are not known. Many interventions
for apnea, including some pharmacologic therapies, phys-
ical or mechanical methods, remain unproven for long-term
efficacy. Further investigation of the pathogenesis and
consequences of apnea in premature infants will help us
understand the long-term risks. In addition, more research
is necessary to clarify optimal treatment regimens.
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